Roldán-Valadez E

Language: Spanish
References: 28
Page: 112-114
PDF size: 87.72 Kb.

Text Extraction

No abstract.

REFERENCES

1. Pennisi E., Human genome. Finally, the book of life and instructions for navigating it. Science, 2000; 288:2304-7.

2. Brown P.O. and D. Botstein, Exploring the new world of the genome with DNA microarrays. Nat Genet, 1999;21:33-7.

3. Wu T.D., Analysing gene expression data from DNA microarrays to identify candidate genes. J Pathol, 2001;195:53-65.

4. Kao C.M., Functional genomic technologies: creating new paradigms for fundamental and applied biology. Biotechnol Prog, 1999;15:304-11.

5. Graves P.R. and T.A. Haystead, Molecular biologist’s guide to proteomics. Microbiol Mol Biol Rev, 2002;66: 39-63; table of contents.

6. Miklos G.L. and R. Maleszka, Integrating molecular medicine with functional proteomics: realities and expectations. Proteomics, 2001;1:30-41.

7. Gillett C.E., et al., Multiple tissue core arrays in histopathology research: a validation study. J Pathol, 2000;192:549-53.

8. Hoos A., et al., Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol, 2001;158:1245-51.

9. Luscombe N.M., D. Greenbaum, and M. Gerstein, What is bioinformatics? A proposed definition and overview of the field. Methods Inf Med, 2001;40:346- 58.

10. Sorlie T., et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A, 2001;98:10869-74.

11. van ‘t Veer, L.J., et al., Gene expression profiling predicts clinical outcome of breast cancer. Nature, 2002;415:530-6.

12. Liefers G.J. and R.A. Tollenaar, Cancer genetics and their application to individualised medicine. Eur J Cancer, 2002;38:872-9.

13. Lakhani S.R. and A. Ashworth, Microarray and histopathological analysis of tumours: the future and the past? Nat Rev Cancer, 2001;1:151-7.

14. Li, K.C., Biomedical imaging in the postgenomic era: opportunities and challenges. Acad Radiol, 2002;9:999-1003.

15. Bremer C. and R. Weissleder, In vivo imaging of gene expression. Acad Radiol, 2001;8:15-23.

16. Luker G.D. and D. Piwnica-Worms, Molecular imaging in vivo with PET and SPECT. Acad Radiol, 2001;8:4-14.

17. Patani G.A. and E.J. LaVoie, Bioisosterism: A Rational Approach in Drug Design. Chem Rev, 1996;96:3147- 3176.

18. Wlodawer A., Rational approach to AIDS drug design through structural biology. Annu Rev Med, 2002;53:595-614.

19. Suleman, A. and E.B. Skibo, A comprehensive study of the active site residues of DT-diaphorase: rational design of benzimidazolediones as DT-diaphorase substrates. J Med Chem, 2002;45:1211-20.

20. Shoemaker R.H., et al., Application of high-throughput, molecular-targeted screening to anticancer drug discovery. Curr Top Med Chem, 2002;2:229-46.

21. Tropsha A. and W. Zheng, Rational principles of compound selection for combinatorial library design. Comb Chem High Throughput Screen, 2002;5:111- 23.

22. Li K.C., Special issue: Molecular imaging. J Magn Reson Imaging, 2002;16:335.

23. Akhurst T. and R. Chisin, Hybrid PET/CT machines: optimized PET machines for the new millennium? J Nucl Med, 2000;41:961-3.

24. Beyer T., et al., A combined PET/CT scanner for clinical oncology. J Nucl Med, 2000;41:1369-79.

25. Charron M., et al., Image analysis in patients with cancer studied with a combined PET and CT scanner. Clin Nucl Med, 2000;25:905-10.

26. Bhatnagar A., R. Hustinx, and A. Alavi, Nuclear imaging methods for non-invasive drug monitoring. Adv Drug Deliv Rev, 2000;41:41-54.

27. Storrs R.W., et al., Paramagnetic polymerized liposomes as new recirculating MR contrast agents. J Magn Reson Imaging, 1995;5:719-24.

28. Sipkins, D.A., et al., Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med, 1998;4:623-6.